01663nam a22003497a 4500 5744 5744 00005744 ES-MaONT 20211006062658.0 200318s2020 be ||||fst|||i001 0 eng d 978-92-846-6037-7 doi 10.2861/114406 ES-MaONT Treatment optimisation in drug development : study : Panel for the Future of Science and Technology / EPRS - European Parliamentary Research Service Brussels : European Union, March 2020 V, 70 p. ; 1 documento PDF isbdcontent texto isbdcontent electrónico rdacarrier recurso en línea Bibliografía: p. 66-70 The development of novel health technologies is a complex and costly process that follows an extensive set of regulatory guidelines and legal provisions intended to ensure that the treatments reach the patients that need them in a highly controlled and standardised manner Reproduction and translation for non-commercial purposes are authorised, provided the source is acknowledged and the European Parliament is given prior notice and sent a copy. Sanidad digital 2065 treatment optimisation clinical drug treatment patient public health industry Parlamento Europeo. Dirección General de Servicios de Estudios Parlamentarios 3675 https://www.europarl.europa.eu/RegData/etudes/STUD/2020/641511/EPRS_STU(2020)641511_EN.pdf 0 Acceso al documento pdf z INF 0 0 0 3 1 6729 01 01 online 2020-03-18 0 1000020176024 2020-03-18 00:00:00 2020-03-18 INF pdf